Thr9
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr9  -  PBK (human)

Site Information
EGIsNFktPskLsEk   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 451735
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 15 ) , immunoassay ( 1 ) , mass spectrometry ( 2 , 4 , 5 , 6 , 7 , 8 , 9 , 11 , 12 , 13 , 14 ) , mutation of modification site ( 16 ) , phospho-antibody ( 1 , 10 , 15 , 16 ) , western blotting ( 1 , 10 )
Disease tissue studied:
breast cancer ( 6 , 9 ) , breast ductal carcinoma ( 6 ) , breast cancer, triple negative ( 6 ) , cervical cancer ( 11 ) , cervical adenocarcinoma ( 11 ) , leukemia ( 13 ) , chronic myelogenous leukemia ( 13 ) , lymphoma ( 1 ) , anaplastic large cell lymphoma ( 1 ) , melanoma skin cancer ( 4 , 10 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Kinases, in vitro:
CDK1 (human) ( 16 )
Treatments:
nocodazole ( 11 , 15 ) , UV ( 10 )

Downstream Regulation
Effects of modification on PBK:
enzymatic activity, induced ( 15 ) , molecular association, regulation ( 16 ) , phosphorylation ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , cytoskeletal reorganization ( 16 ) , signaling pathway regulation ( 1 )
Induce interaction with:
CCNB1 (human) ( 16 ) , CDK1 (human) ( 16 ) , TUBA4A (human) ( 16 )

Disease / Diagnostics Relevance
Relevant diseases:
cancer, squamous cell carcinoma ( 1 )

References 

1

Roh E, et al. (2018) Targeting PRPK and TOPK for skin cancer prevention and therapy. Oncogene
29904102   Curated Info

2

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

3

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

4

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

5

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

6

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

7

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

8

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

9

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

10

Zykova TA, et al. (2010) T-LAK cell-originated protein kinase (TOPK) phosphorylation of Prx1 at Ser-32 prevents UVB-induced apoptosis in RPMI7951 melanoma cells through the regulation of Prx1 peroxidase activity. J Biol Chem 285, 29138-46
20647304   Curated Info

11

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

12

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

13

Possemato A (2007) CST Curation Set: 2724; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

14

Possemato A (2007) CST Curation Set: 2653; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

15

Dougherty JD, et al. (2005) PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase. J Neurosci 25, 10773-85
16291951   Curated Info

16

Matsumoto S, et al. (2004) Characterization of a MAPKK-like protein kinase TOPK. Biochem Biophys Res Commun 325, 997-1004
15541388   Curated Info